These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29759562)

  • 1. Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer.
    Hurtado M; Sankpal UT; Ranjan A; Maram R; Vishwanatha JK; Nagaraju GP; El-Rayes BF; Basha R
    Crit Rev Oncol Hematol; 2018 Jun; 126():201-207. PubMed ID: 29759562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution.
    Basha R; Connelly SF; Sankpal UT; Nagaraju GP; Patel H; Vishwanatha JK; Shelake S; Tabor-Simecka L; Shoji M; Simecka JW; El-Rayes B
    J Nutr Biochem; 2016 May; 31():77-87. PubMed ID: 27133426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
    Sankpal UT; Nagaraju GP; Gottipolu SR; Hurtado M; Jordan CG; Simecka JW; Shoji M; El-Rayes B; Basha R
    Oncotarget; 2016 Jan; 7(3):3186-200. PubMed ID: 26672603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
    Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
    Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer.
    Nagaraju GP; Zhu S; Wen J; Farris AB; Adsay VN; Diaz R; Snyder JP; Mamoru S; El-Rayes BF
    Cancer Lett; 2013 Dec; 341(2):195-203. PubMed ID: 23933177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In Vitro.
    Mahmud M; Piwoni A; Filipczak N; Janicka M; Gubernator J
    PLoS One; 2016; 11(12):e0167787. PubMed ID: 27936114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
    Veschi S; De Lellis L; Florio R; Lanuti P; Massucci A; Tinari N; De Tursi M; di Sebastiano P; Marchisio M; Natoli C; Cama A
    J Exp Clin Cancer Res; 2018 Sep; 37(1):236. PubMed ID: 30241558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
    Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
    Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.
    Marsh Rde W; George T
    Curr Gastroenterol Rep; 2006 Apr; 8(2):111-20. PubMed ID: 16533473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
    Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
    Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.
    Mercalli A; Sordi V; Formicola R; Dandrea M; Beghelli S; Scarpa A; Di Carlo V; Reni M; Piemonti L
    Br J Cancer; 2007 May; 96(9):1358-67. PubMed ID: 17426706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of novel
    Xie X; Tu J; You H; Hu B
    Drug Des Devel Ther; 2017; 11():1439-1451. PubMed ID: 28553074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative chemoradiation therapy for pancreatic cancer.
    Evans DB; Pisters PW
    Surg Clin North Am; 2001 Jun; 81(3):709-13. PubMed ID: 11459284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
    Czito BG; Willett CG; Bendell JC; Morse MA; Tyler DS; Fernando NH; Mantyh CR; Blobe GC; Honeycutt W; Yu D; Clary BM; Pappas TN; Ludwig KA; Hurwitz HI
    J Clin Oncol; 2006 Feb; 24(4):656-62. PubMed ID: 16446337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles.
    Wang J; Ma W; Tu P
    Macromol Biosci; 2015 Sep; 15(9):1252-61. PubMed ID: 25981672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis.
    Yamaguchi Y; Kasukabe T; Kumakura S
    Int J Oncol; 2018 Mar; 52(3):1011-1022. PubMed ID: 29393418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia.
    Suklabaidya S; Das B; Ali SA; Jain S; Swaminathan S; Mohanty AK; Panda SK; Dash P; Chakraborty S; Batra SK; Senapati S
    Oncotarget; 2016 Jul; 7(27):41825-41842. PubMed ID: 27259232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy for pancreatic cancer.
    Arbuck SG
    Baillieres Clin Gastroenterol; 1990 Dec; 4(4):953-68. PubMed ID: 2078794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.
    Keedy VL; Berlin J
    Curr Treat Options Oncol; 2006 Sep; 7(5):381-8. PubMed ID: 16904055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.
    Ulivi P; Arienti C; Zoli W; Scarsella M; Carloni S; Fabbri F; Tesei A; Chiadini E; Orlandi A; Passeri D; Zupi G; Milandri C; Silvestrini R; Amadori D; Leonetti C
    Curr Cancer Drug Targets; 2010 Sep; 10(6):600-10. PubMed ID: 20491617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.